EMA Authorised: Quviviq (daridorexant hydrochloride) — Idorsia Pharmaceuticals Deutschland GmbH

View source ↗

Summary

EU has authorised Quviviq (daridorexant hydrochloride) by Idorsia for sleep initiation and maintenance disorders. This approval provides a new treatment option …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• QUVIVIQ (daridorexant)

Snippet

Status: Authorised. Therapeutic area: Sleep Initiation and Maintenance Disorders. MAH: Idorsia Pharmaceuticals Deutschland GmbH. Decision date: 12/03/2026